The EU Vaccine Industry in Figures

Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.

Find out more

Vaccines: a tool for spending smart

Effective vaccination programmes ease pressure on budgets and allow resources to focus on other healthcare areas and medical innovation

Find out how

-->

Prevention First

Vaccination at the Heart of Public Health. Vaccines Europe calls on EU policy-makers to develop a comprehensive vaccination strategy through five core policy asks.

Read more

Vaccine Market Access in the EU

How long for a vaccine to reach European Population? 6,4 years is the median time lag between marketing authorisation and effective population access

Find out more

An industry for healthy lives

As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe as well as small and medium sized enterprises.
Find out more about our services, the opportunites we offer and how to become a member.

Find out how to become a member

Latest News

RSS

Vaccines Europe We-Wont-Rest Campaign

2017 11 12 Written by Vaccines Europe

Vaccines Europe launched the We-Wont-Rest Campaign in November 2017. The new campaign focuses on the passion, commitment and dedication of individuals, teams and companies in the vaccine industry to discovering and developing new vaccines for patients. We’re telling our industry’s innovation story and using #WeWontRest to start the public discussion on the value of innovation and the future of healthcare in Europe.
Access the campaign page here and read about the pledges industry experts have made here.

Early Career Research Prize in Vaccinology R&D

2017 09 29 Written by Vaccines Europe

The Early Career Research Prize in Vaccinology R&D is awarded by the International Union of Immunological Societies (IUIS) with the contribution of Vaccines Europe. The objective is to promote and foster a younger generation of scientists in the early stages of their career.

The prize rewards significant achievements in Vaccine R&D, including the discovery of new vaccine antigens, new vaccines design, understanding the basics of the immune response, new technologies that will improve the future of vaccines and vaccination and that are supported by proof-of-concept data (preclinical and clinical).

For information regarding application criteria, follow this link and the Promotion Flyer.

Pascale Mauran appointed as Vaccines Europe President

2017 09 11 Written by Vaccines Europe

Vaccines Europe is pleased to announce that Pascale Mauran, Vice-President, IDM Vaccines Commercial Development at Pfizer, has been officially appointed as the new Vaccines Europe President. Pascale Mauran has been representing Pfizer on the Vaccines Europe Board for four years now, out of which one and half year as Vaccines Europe Vice-President. She brings solid experience and expertise on vaccines to help drive the development of the Vaccines Europe objectives. Pascale Mauran’s appointment as President will start immediately and will run for the next two years.

Pascale Mauran stated: “I am delighted to take the responsibility of President of Vaccines Europe and continue to drive Vaccines Europe strategy and vision in this significant momentum for vaccination in Europe with the EU Joint Action on Vaccination and all other important EU initiatives underway”.

Vaccines Europe expresses its gratitude to its former President Andrea Rappagliosi, for his strong leadership dedicated to Vaccines Europe over the past 5 years.

For more information, please contact:
Magdalena R. de Azero, Executive Director, Vaccines Europe
Email: magdalena.deazero@vaccineseurope.eu

EFPIA, EBE and Vaccines Europe Back EU Leadership in Sustainable, Collaborative Fight Against AMR

2017 06 29 Written by Vaccines Europe

The launch of the European Commission’s Action Plan on Antimicrobial Resistance (AMR) confirms the EU’s determination to take a leading role in combatting this phenomenon, by proposing concrete and innovative solutions to benefit patients worldwide.

Read the Joint Statement here.

Read more…

See all News